The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively.
Read Full
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
